Inpatient Management of Diabetes: Admission to Discharge
Silvio E. Inzucchi, MD
Professor of Medicine and Clinical Director
Department of Endocrinology
Yale University School of Medicine
Director, Yale Diabetes Center
Yale-New Haven Hospital
New Haven, Connecticut
Achieving optimal outcomes for hospitalized patients with diabetes requires implementation of current, evidence-based guidelines and protocols for glycemic control. Uncontrolled hyperglycemia in the inpatient setting is a common occurrence and is associated with an increase in morbidity and mortality. In this video, Dr. Inzucchi presents the rationale for implementing updated glycemic control strategies, including the latest recommendations from the American Diabetes Association and American Association of Clinical Endocrinologists. A focused approach based on different patient characteristics and clinical settings within the hospital is discussed. Effective discharge planning to ensure continuity of care between inpatient and outpatient management is also emphasized.
Method of Participation and Evaluation
To participate in this CME activity, please read the following information and click "Launch Program" at the bottom of this page. Complete the online evaluation at the conclusion of the activity. You may print your certificate immediately after completion of the evaluation. Please note: To view this program you need a computer with an Internet browser and audio and video capabilities.
Up to 0.5 AMA PRA Category 1 Credit™
After taking part in this CME activity, learners should be better able to:
- Evaluate the association between inpatient hyperglycemia and adverse clinical outcomes
- Develop and implement critical pathways for glycemic control in the hospital based on patient characteristics and point of care (eg, ICU, MICU, general medical or surgical ward)
- Synthesize current guidelines and protocols and apply them to patient care in various clinical settings
- Implement a discharge plan to facilitate a smooth transition to outpatient care
Silvio E. Inzucchi, MD, has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, Inc., Medtronic, Inc., Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.; has received honoraria from Novo Nordisk Inc.; and has received research support from Eli Lilly and Company.
The Foundation for Improving Patient Outcomes staff and the independent peer reviewer report nothing to disclose.
CME Credit Designations
The Foundation for Improving Patient Outcomes (FFIPO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
FFIPO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of the activity.
This activity is eligible for up to 0.5 hour of credit in Category 2-A of the American Osteopathic Association.